Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Lyra Therapeutics, Inc. | Executive Chair, Director | Common Stock | 537K | $1.59M | $2.96 | Mar 18, 2024 | Direct |
Kadmon Holdings, Inc. | President, CEO, Director | Common Stock | 0 | $9.50 | Nov 9, 2021 | Direct | |
Kadmon Holdings, Inc. | President, CEO, Director | Equity Appreciation Rights Unit | 0 | $3.50 | Nov 9, 2021 | Direct | |
Kadmon Holdings, Inc. | President, CEO, Director | Performance Stock Option(right to buy) | 0 | $5.44 | Nov 9, 2021 | Direct | |
Kadmon Holdings, Inc. | President, CEO, Director | Stock Appreciation Right | 0 | $5.86 | Nov 9, 2021 | Direct | |
Kadmon Holdings, Inc. | President, CEO, Director | Stock Option (right to buy) | 0 | $5.54 | Nov 9, 2021 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
PCSC | Perceptive Capital Solutions Corp | Jun 11, 2024 | 0 | $0 | 3 | Jun 11, 2024 | Director |
LYRA | Lyra Therapeutics, Inc. | Mar 18, 2024 | 1 | $0 | 4 | Mar 20, 2024 | Executive Chair, Director |
LYRA | Lyra Therapeutics, Inc. | Nov 10, 2023 | 1 | $74.1K | 4 | Nov 13, 2023 | Executive Chair, Director |
LYRA | Lyra Therapeutics, Inc. | Jan 31, 2023 | 1 | $0 | 4 | Feb 2, 2023 | Executive Chair, Director |
LYRA | Lyra Therapeutics, Inc. | Jun 16, 2022 | 1 | $0 | 4 | Jun 21, 2022 | Executive Chair, Director |
LYRA | Lyra Therapeutics, Inc. | Apr 12, 2022 | 1 | $1M | 4 | Apr 13, 2022 | Executive Chair, Director |
LYRA | Lyra Therapeutics, Inc. | Feb 16, 2022 | 1 | $0 | 4 | Feb 18, 2022 | Executive Chair, Director |
LYRA | Lyra Therapeutics, Inc. | Feb 16, 2022 | 0 | $0 | 3 | Feb 18, 2022 | Executive Chair, Director |
KDMN | Kadmon Holdings, Inc. | Nov 9, 2021 | 6 | $25.8M | 4 | Nov 9, 2021 | President, CEO, Director |
KDMN | Kadmon Holdings, Inc. | May 13, 2021 | 1 | $89K | 4 | May 17, 2021 | President, CEO, Director |